Instructions for Urdox (Ursodeoxycholic acid) capsules
English product name
Urdoxa
Release form Urdox
caps. 250 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 pcs
Description Urdox:
Capsules are solid gelatine, size №0, white or almost white, opaque; The capsule contents are white or almost white powder or granulate.
1 cap.
ursodeoxycholic acid 250 mg
Auxiliary substances: cornstarch - 73 mg, silica colloidal anhydrous - 5 mg, magnesium stearate - 2 mg.
The composition of the capsule of solid gelatine: gelatin - 98%, titanium dioxide (E171) - 2%.
ATC codes
A05AA02 Ursodeoxycholic acid
Clinical-pharmacological groups / Group affiliation
Hepatoprotector with cholelytic and cholelititic action
Active substance
ursodeoxycholic acid
Pharmacotherapy group Urdox:
Hepatoprotective agent
Storage Conditions
The drug should be stored in a dry, light-proof place, inaccessible to children at a temperature not higher than 25 ° C.
Best before date Urdox
The shelf life is four years.
Do not apply after the expiry date indicated on the package.
Pharmacological effect Urdox:
The inventive hepatoprotective agent exhibits a cholelytic, cholelytolithic, hypocholesterolemic, hypolipidemic and immunomodulating action.
It is embedded in the hepatocyte membrane, stabilizes its structure and protects hepatocyte from the damaging effect of bile acid salts, thus reducing their cytotoxic effect. In cholestasis, it activates Ca2+-dependent alpha-protease and stimulates exocytosis, reducing the concentration of toxic bile acids (henodeoxycholic, lithocholic, deoxycholic, etc.), the concentrations of which in patients with chronic liver diseases are elevated.
It competitively reduces the absorption of lipophilic bile acids in the intestine, increases their "fractional" turnover in enterohepatic circulation, induces cholerez, stimulates bile passage and elimination of toxic bile acids through the intestines.
It shields non-polar bile acids (henodeoxycholic), which form mixed (non-toxic) mycelles.
Testimony Urdox:
- primary biliary cirrhosis in the absence of signs of discompensation (symptomatic treatment);
- dissolving cholesterol gallbladder stones;
- biliary reflux gastritis;
- primary sclerosing cholangitis;
- alcoholic liver disease;
- non-alcoholic steatohepatitis;
- cystic fibrosis (cystic fibrosis);
- chronic hepatitis of different origins;
- biliary dyskinesia.
Method of use, course and dosage:
Urdox® capsules are taken inside without chewing, being washed down with a little water.
Symptomatic treatment of primary biliary cirrhosis
The daily dose depends on the body weight and ranges from 3 to 7 capsules (approximately 14±2 mg of ursodeoxycholic acid per 1 kg body weight). In the first 3 months of treatment, Urdox® should be divided into several treatments during the day. After the improvement of the liver indicators, the daily dose of the drug can be taken 1 time in the evening.
Application for kidney disorders
Contraindication: Pronounced kidney dysfunction.
Use in liver disorders
Contraindication: Pronounced liver dysfunction, cirrhosis of the liver in the stage of discompensation.
Terms of Sale
The drug is prescription.
Use in children Urdox
Ursodeoxycholic acid has no age restrictions, but children under 3 years of age are not recommended to use the drug in this form.
It is used with caution in children between 3 and 4 years of age, as it may be difficult to swallow capsules.
For children over 3 years of age, ursodeoxycholic acid is administered individually at 10-20 mg/kg/day.
- Nosology Urdox (ICD codes)
- B18
- Chronic viral hepatitis
- E84
- Cystic fibrosis
- K70
- Alcoholic liver disease
- K73
- Chronic hepatitis not classified elsewhere
- K74
- Fibrosis and cirrhosis
- K76.0
- Fatty liver (liver degeneration) not classified elsewhere
- K80
- Gallstone disease [cholelitiasis] (incl. hepatic colic)
- K82.8
- Other refined diseases of the gallbladder and bubble duct (including dyskinesia)
- K83.0
- Holangit
